Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:LMAT

LeMaitre Vascular Q3 2026 Earnings Date & Estimates

LeMaitre Vascular logo
$80.69 +1.05 (+1.32%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$80.71 +0.02 (+0.02%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LeMaitre Vascular is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 5:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
5:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from LeMaitre Vascular in Q3 2026

LeMaitre Vascular is expected to post earnings of $0.6860 per share on revenue of $67.39 million. In the same quarter a year earlier LeMaitre Vascular reported $0.62 per share on revenue of $61.05 million. LeMaitre Vascular last reported on August 4, 2026, posting $0.74 per share and missing the $0.8070 consensus estimate. LeMaitre Vascular has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.6860
Expected Revenue
$67.39 million
Prior-Year EPS
$0.62
Prior-Year Revenue
$61.05 million
Expected EPS Growth
+10.6%
Expected Revenue Growth
+10.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.74 (Missed by -$0.0670)
Last Quarter Revenue
$70.38 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

LeMaitre Vascular Q3 2026 Earnings FAQ

LeMaitre Vascular (NASDAQ:LMAT) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes.

LeMaitre Vascular's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect LeMaitre Vascular to post earnings of $0.6860 per share for Q3 2026.

The consensus revenue estimate for LeMaitre Vascular is $67.39 million for Q3 2026.

LeMaitre Vascular Earnings Headlines

GE HealthCare Technologies (NASDAQ:GEHC) & LeMaitre Vascular (NASDAQ:LMAT) Head to Head Comparison
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084144
Barrington Sticks to Its Buy Rating for Lemaitre Vascular (LMAT)
October 3, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LMAT/pressreleases/4930417/barrington-sticks-to-its-buy-rating-for-lemaitre-vascular-lmat/
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
October 10 at 1:00 AM  |  Stansberry Research (Ad)
LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine
October 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951243-lemaitre-stock-vascular-q2-miss-hides-stronger-acquisition-machine
Is LeMaitre Vascular (LMAT) A Bargain Following Its 90 Day Pullback?
September 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/lemaitre-vascular-lmat-bargain-following-221522242.html
LeMaitre Vascular (LMAT) Stock Looks Fully Priced On Its 57% Five Year Run
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/lemaitre-vascular-lmat-stock-looks-032504037.html
See More LeMaitre Vascular Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LeMaitre Vascular? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LeMaitre Vascular and other key companies, straight to your email.

About LeMaitre Vascular

LeMaitre Vascular (NASDAQ:LMAT) is a medical device company that develops, manufactures and markets products used primarily in the treatment of peripheral vascular disease. Its products are designed for vascular surgeons and other specialists performing procedures on blood vessels outside the heart and brain, including procedures involving the carotid, lower-extremity and aortic vascular systems.

The company’s product portfolio includes biologic and synthetic vascular grafts, angioplasty and thrombectomy catheters, valvulotomes, carotid shunts, vascular clamps and other devices used in open and minimally invasive vascular surgery. LeMaitre also offers products intended to support vessel repair, bypass procedures and the management of vascular access and blood flow during surgery.

Headquartered in Burlington, Massachusetts, LeMaitre Vascular serves hospitals and healthcare providers in the United States and international markets through a combination of direct sales organizations and distributors. The company was founded in 1983 by George W. LeMaitre, who continues to serve as its chief executive officer.

View LeMaitre Vascular Profile
Earnings Tools